A Phase II, 12-month, Double-blind, Placebo-controlled, Dose-finding, Multicenter Study to Evaluate the Safety, Tolerability, and Disease Modifying Efficacy of Daily Oral AAE581 (10, 25 and 50 mg Tablets) in Patients With Painful Knee Osteoarthritis, Kellgren-Lawrence Grade 3 by X-ray
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Balicatib (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Actual patient number (223) added, additional location (Germany) added as reported by ClinicalTrials.gov.
- 12 Dec 2007 Status changed from in progress to completed.